IMNM Immunome, Inc.

NASDAQ
$24.67

Immunome, Inc. (IMNM) Insider Activity

What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.

30D 90D 6M 1Y
Insider signal Moderately bearish Selling ran elevated versus IMNM's own trailing one-year pace, with 92% of sale value under a prearranged plan.
Cluster activity 0 buyers in the last 30 days 0 buyers in the last 90 days 3 sellers in the last 90 days
Insiders buying
2
5 transactions
Insiders selling
7
25 transactions
Purchases
$808.4K
40,950 shares
Sales
$18.8M
832,248 shares
Net activity
-$18.0M
purchases less sales

How much of that selling was preplanned? 92% planned / 8% discretionary

10b5-1 plan sales $17.3M 21 transactions · 756,748 shares
Discretionary sales $1.5M 4 transactions · 75,500 shares

Largest single sale: $2.3M.

Where they traded

Buy Sell Dot area is proportional to transaction value.

Last open-market purchase: June 5, 2026 , by BIENAIME JEAN JACQUES .

Recent open-market activity

Date Insider Role Action Shares Price Value Held after
Barchas Isaac Director Sell 10b5-1 11,048 $27.25 $301.1K 92,211 −10.7% of holding
Barchas Isaac Director Sell 10b5-1 62,291 $26.23 $1.6M None left
Barchas Isaac Director Sell 10b5-1 10,125 $26.07 $264.0K 62,291 −14% of holding
Barchas Isaac Director Sell 10b5-1 15,248 $26.06 $397.4K 72,416 −17.4% of holding
Barchas Isaac Director Sell 10b5-1 20,840 $26.06 $543.1K 87,664 −19.2% of holding
Horn Kinney CHIEF BUSINESS OFFICER Sell 10b5-1 90,616 $25.09 $2.3M None left
Barchas Isaac Director Sell 10b5-1 16,906 $24.20 $409.1K 108,504 −13.5% of holding
Horn Kinney CHIEF BUSINESS OFFICER Sell 10b5-1 1,092 $25.00 $27.3K None left
Barchas Isaac Director Sell 10b5-1 83,094 $24.11 $2.0M 125,410 −39.9% of holding
Barchas Isaac 2 fills Director Sell 10b5-1 100,000 $22.59 $2.3M 232,839 −30% of holding
Lechleider Robert 3 fills Chief Medical Officer Sell 10b5-1 55,000 $22.62 $1.2M 48,091 −53.4% of holding
Barchas Isaac Director Sell 10b5-1 101,050 $21.12 $2.1M 308,504 −24.7% of holding
Lechleider Robert 2 fills Chief Medical Officer Sell 10b5-1 55,000 $19.85 $1.1M 30,225 −64.5% of holding
Rosett Max Chief Financial Officer Sell 10b5-1 60,000 $18.23 $1.1M 54,037 −52.6% of holding
BIENAIME JEAN JACQUES 3 fills Director Buy 10,500 $19.45 $204.3K 43,415
BIENAIME JEAN JACQUES 2 fills Director Sell 10,500 $19.41 $203.8K 42,915 −19.7% of holding
BIENAIME JEAN JACQUES Director Buy 5,000 $20.70 $103.5K 43,415
Rosett Max 2 fills Chief Financial Officer Sell 10b5-1 65,000 $21.92 $1.4M 55,381 −54% of holding
Higgins Jack Chief Scientific Officer Sell 10b5-1 9,438 $21.64 $204.2K 22,000 −30% of holding
SIEGALL CLAY B President and CEO Buy 25,450 $19.67 $500.6K 690,704
WAGENHEIM PHILIP Director Sell 28,200 $20.65 $582.3K 341,147 −7.6% of holding
WAGENHEIM PHILIP Director Sell 36,800 $20.47 $753.3K 369,347 −9.1% of holding

Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.